Biosyngen’s BRG01 Earns Orphan Drug Designation from US FDA for Nasopharyngeal Carcinoma
Biosyngen, a leading cell therapy developer based in Guangzhou, has announced that it has received...
Biosyngen
Biosyngen Receives US FDA IND Approval for T-Cell Redirection Therapy for EBV-Positive Lymphoma
Biosyngen Pte Ltd, a cell and gene therapy (CGT) biotech with operations in Singapore and...
Biosyngen’s BRG01 Gets FDA Nod for NPC Clinical Study
Cell and gene therapy (CGT) specialist Biosyngen Pte Ltd has announced receiving approval from the...
Biosyngen’s First-in-Class Drug Candidate BRG01 Accepted for IND Review
Biosyngen has announced that its investigational new drug (IND) filing for the first-in-class (FIC) drug...
Biosyngen to Establish Cell Therapy GMP Facility in Singapore
Biosyngen has announced plans to establish a Cell Therapy GMP Facility in Singapore, aimed at...